Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

U0800000

Ursodeoxycholic acid

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

3α,7β-Dihydroxy-5β-cholan-24-oic acid, 5β-Cholan-24-oic acid-3α,7β-diol, 7β-Hydroxylithocholic acid, UDCS

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C24H40O4
Número CAS:
128-13-2
Peso molecular:
392.57
Beilstein:
3219888
Número MDL:
MFCD00003680
Código UNSPSC:
41116107
ID de substância PubChem:
329827593
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

ursodeoxycholic acid

fabricante/nome comercial

EDQM

pf

203-204 °C (lit.)

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1

chave InChI

RUDATBOHQWOJDD-UZVSRGJWSA-N

Informações sobre genes

human ... NR1H4(9971)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Ursodeoxycholic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H315,H319

Classificações de perigo

Eye Irrit. 2 - Skin Irrit. 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 6

1 of 6

Taurolithocholic acid 3-sulfate disodium salt

Sigma-Aldrich

T0512

Taurolithocholic acid 3-sulfate disodium salt

Tauroursodeoxycholic Acid, Sodium Salt Tauroursodeoxycholic is a detergent useful for the solubilization of lipids and membrane-bound proteins.

Millipore

580549

Tauroursodeoxycholic Acid, Sodium Salt

Chenodeoxycholic acid

Sigma-Aldrich

C9377

Chenodeoxycholic acid

Lithocholic acid ≥95%

Sigma-Aldrich

L6250

Lithocholic acid

Cholic acid from bovine and/or ovine, ≥98%

Sigma-Aldrich

C1129

Cholic acid

Ácido desoxicólico ≥98% (HPLC)

Sigma-Aldrich

D2510

Ácido desoxicólico

Marco Carbone et al.
Gastroenterology, 144(3), 560-569 (2012-12-19)
BACKGROUND, & AIMS: Studies of primary biliary cirrhosis (PBC) phenotypes largely have been performed using small and selected populations. Study size has precluded investigation of important disease subgroups, such as men and young patients. We used a national patient cohort
Li-Na Zhang et al.
Hepatology (Baltimore, Md.), 58(1), 264-272 (2013-02-15)
The biochemical response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis is a strong predictor of long-term outcome and thus facilitates the rapid identification of patients needing new therapeutic approaches. Numerous criteria for predicting outcome of treatment have been studied
R A Rubin et al.
Annals of internal medicine, 121(3), 207-218 (1994-08-01)
To explain the rationale supporting the use of ursodiol (ursodeoxycholic acid) for the treatment of patients with cholesterol gallstones and chronic liver diseases and to describe the results obtained in clinical trials. Personal databases of the authors and MEDLINE were
Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.
Keith Lindor
The New England journal of medicine, 357(15), 1524-1529 (2007-10-12)
Ursodeoxycholic acid in chronic hepatitis C.
Raoul Poupon et al.
Gut, 56(12), 1652-1653 (2007-11-14)
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica